Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 83 articles: HTML format

Single Articles

May 2024
1. HE W, Wang M, Zhang X, Wang Y, et al
   Estrogen induces LCAT to maintain cholesterol homeostasis and suppress hepatocellular carcinoma development.
   Cancer Res. 2024 May 8. doi: 10.1158/0008-5472.CAN-23-3966.
   PubMed     Abstract available
   
   
   
2. ZHANG R, Li S, Schippers K, Li Y, et al
   Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate beta-Catenin Signaling.
   Cancer Res. 2024;84:1443-1459.
   PubMed     Abstract available
   
   
   March 2024
3. HUANG J, Tsang WY, Fang XN, Zhang Y, et al
   FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma.
   Cancer Res. 2024;84:855-871.
   PubMed     Abstract available
   
   
   
4. WENG J, Wang Z, Hu Z, Xu W, et al
   Repolarization of immunosuppressive macrophages by targeting SLAMF7-regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy.
   Cancer Res. 2024 Mar 14. doi: 10.1158/0008-5472.CAN-23-3106.
   PubMed     Abstract available
   
   
   
5. LIAO H, Chen X, Wang H, Lin Y, et al
   Whole-genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers.
   Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-3298.
   PubMed     Abstract available
   
   
   
6. WAN S, He QY, Yang Y, Liu F, et al
   SPARC stabilizes ApoE to induce cholesterol-dependent invasion and sorafenib resistance in hepatocellular carcinoma.
   Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-2889.
   PubMed     Abstract available
   
   
   February 2024
7. WANG Y, Cheng C, Lu Y, Lian Z, et al
   beta-catenin Activation Reprograms Ammonia Metabolism to Promote Senescence Resistance in Hepatocellular Carcinoma.
   Cancer Res. 2024 Feb 28. doi: 10.1158/0008-5472.CAN-23-0673.
   PubMed     Abstract available
   
   
   
8. SONG M, Zhang C, Cheng S, Ouyang D, et al
   DNA of neutrophil extracellular traps binds TMCO6 to impair CD8+ T-cell immunity in hepatocellular carcinoma.
   Cancer Res. 2024 Feb 21. doi: 10.1158/0008-5472.CAN-23-2986.
   PubMed     Abstract available
   
   
   
9. LIU X, Wang X, Yang Q, Luo L, et al
   Th17 cells secrete TWEAK to trigger epithelial-mesenchymal transition and promote colorectal cancer liver metastasis.
   Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2123.
   PubMed     Abstract available
   
   
   January 2024
10. ZHANG X, Su T, Wu Y, Cai Y, et al
    N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression.
    Cancer Res. 2024 Jan 19. doi: 10.1158/0008-5472.CAN-23-1916.
    PubMed     Abstract available
    
    
    
11. MU M, Huang CX, Qu C, Li PL, et al
    Targeting ferroptosis-elicited inflammation suppresses hepatocellular carcinoma metastasis and enhances sorafenib efficacy.
    Cancer Res. 2024 Jan 17. doi: 10.1158/0008-5472.CAN-23-1796.
    PubMed     Abstract available
    
    
    December 2023
12. DATTA J, Kutay H, Nasser MW, Nuovo GJ, et al
    Retraction: Methylation Mediated Silencing of MicroRNA-1 Gene and Its Role in Hepatocellular Carcinogenesis.
    Cancer Res. 2023;83:4181.
    PubMed    
    
    
    
13. MAJUMDER S, Roy S, Kaffenberger T, Wang B, et al
    Retraction: Loss of Metallothionein Predisposes Mice to Diethylnitrosamine-Induced Hepatocarcinogenesis by Activating NF-kappaB Target Genes.
    Cancer Res. 2023;83:4179.
    PubMed    
    
    
    November 2023
14. ZHUANG Q, Dai Z, Xu X, Bai S, et al
    RNA methyltransferase FTSJ3 regulates the type I interferon pathway to promote hepatocellular carcinoma immune evasion.
    Cancer Res. 2023 Nov 14. doi: 10.1158/0008-5472.CAN-23-2049.
    PubMed     Abstract available
    
    
    
15. CHEN Z, Zhang G, Ren X, Yao Z, et al
    Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer.
    Cancer Res. 2023;83:3544-3561.
    PubMed     Abstract available
    
    
    September 2023
16. SU T, Zhang N, Wang T, Zeng J, et al
    Super enhancer-regulated lncRNA LINC01089 induces alternative splicing of DIAPH3 to drive hepatocellular carcinoma metastasis.
    Cancer Res. 2023 Sep 26. doi: 10.1158/0008-5472.CAN-23-0544.
    PubMed     Abstract available
    
    
    
17. HUNG MH, Wang XW
    Targeting WNT/beta-catenin via modulating EZH2 function - a new chapter in the treatment of beta-catenin mutant hepatocellular carcinoma?
    Cancer Res. 2023 Sep 25. doi: 10.1158/0008-5472.CAN-23-2921.
    PubMed     Abstract available
    
    
    August 2023
18. ZHENG Y, Zhou R, Cai J, Yang N, et al
    Matrix stiffness triggers lipid metabolic crosstalk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases.
    Cancer Res. 2023 Aug 23:CAN-23-0025. doi: 10.1158/0008-5472.CAN-23-0025.
    PubMed     Abstract available
    
    
    June 2023
19. MATSUMOTO S, Harada A, Seta M, Akita M, et al
    Wnt Signaling Stimulates Cooperation between GREB1 and HNF4alpha to Promote Proliferation in Hepatocellular Carcinoma.
    Cancer Res. 2023 Jun 22:OF1-OF16. doi: 10.1158/0008-5472.CAN-22-3518.
    PubMed     Abstract available
    
    
    
20. ZHANG Q, Wei T, Yan L, Zhu S, et al
    Hypoxia-responsive lncRNA AC115619 encodes a micropeptide that suppresses m6A modifications and hepatocellular carcinoma progression.
    Cancer Res. 2023 Jun 16:CAN-23-0337. doi: 10.1158/0008-5472.CAN-23-0337.
    PubMed     Abstract available
    
    
    
21. SCHEPERS EJ, Glaser K, Zwolshen HM, Hartman SJ, et al
    Structural and Functional Impact of Posttranslational Modification of Glypican-3 on Liver Carcinogenesis.
    Cancer Res. 2023;83:1933-1940.
    PubMed     Abstract available
    
    
    May 2023
22. BEI Y, He J, Dong X, Wang Y, et al
    Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma.
    Cancer Res. 2023 May 19:CAN-23-0510. doi: 10.1158/0008-5472.CAN-23-0510.
    PubMed     Abstract available
    
    
    
23. ZHOU Q, Li L, Sha F, Lei Y, et al
    PTTG1 reprograms asparagine metabolism to promote hepatocellular carcinoma progression.
    Cancer Res. 2023 May 9:CAN-22-3561. doi: 10.1158/0008-5472.CAN-22-3561.
    PubMed     Abstract available
    
    
    
24. MUNSON PV, Adamik J, Hartmann FJ, Favaro PMB, et al
    Polyunsaturated Fatty Acid-Bound alpha-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism.
    Cancer Res. 2023;83:1543-1557.
    PubMed     Abstract available
    
    
    April 2023
25. WOOD CS, Pennel KAF, Leslie H, Legrini A, et al
    Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases.
    Cancer Res. 2023;83:1329-1344.
    PubMed     Abstract available
    
    
    
26. FANG JH, Chen JY, Zheng JL, Zeng HX, et al
    Fructose Metabolism in Tumor Endothelial Cells Promotes Angiogenesis by Activating AMPK Signaling and Mitochondrial Respiration.
    Cancer Res. 2023;83:1249-1263.
    PubMed     Abstract available
    
    
    December 2022
27. DHANASEKARAN R, Hansen AS, Park J, Lemaitre L, et al
    MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma that is Reversible Through Restoration of Pro-Inflammatory Macrophages.
    Cancer Res. 2022 Dec 16:CAN-22-0232. doi: 10.1158/0008-5472.CAN-22-0232.
    PubMed     Abstract available
    
    
    
28. HAN J, Meng J, Chen S, Wang X, et al
    Correction: YY1 Complex Promotes Quaking Expression via Super-Enhancer Binding during EMT of Hepatocellular Carcinoma.
    Cancer Res. 2022;82:4694.
    PubMed    
    
    
    
29. CHENG X, Tan X, Wang W, Zhang Z, et al
    Long-chain acylcarnitines induce senescence of invariant natural killer T cells in hepatocellular carcinoma.
    Cancer Res. 2022 Dec 13:CAN-22-2273. doi: 10.1158/0008-5472.CAN-22-2273.
    PubMed     Abstract available
    
    
    
30. TEIJEIRA A, Garasa S, Luri-Rey C, de Andrea C, et al
    Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy.
    Cancer Res. 2022;82:4373-4385.
    PubMed     Abstract available
    
    
    November 2022
31. WUESTEFELD A, Iakovleva V, Yap SXL, Ong ABL, et al
    A pro-regenerative environment triggers premalignant to malignant transformation of senescent hepatocytes.
    Cancer Res. 2022 Nov 30:CAN-22-1477. doi: 10.1158/0008-5472.CAN-22-1477.
    PubMed     Abstract available
    
    
    
32. ZHU X, Song G, Zhang S, Chen J, et al
    Asialoglycoprotein Receptor 1 Functions as a Tumor Suppressor in Liver Cancer via Inhibition of STAT3.
    Cancer Res. 2022;82:3987-4000.
    PubMed     Abstract available
    
    
    October 2022
33. DUDA DG, Jain RK
    Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.
    Cancer Res. 2022;82:3665-3667.
    PubMed     Abstract available
    
    
    September 2022
34. XIAO Y, Li Y, Shi D, Wang X, et al
    MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling to facilitate metastasis in hepatocellular carcinoma.
    Cancer Res. 2022 Sep 16. pii: 709244. doi: 10.1158/0008-5472.CAN-22-1203.
    PubMed     Abstract available
    
    
    
35. MAN K, Pang L, Yeung OWH, Ng KTP, et al
    Postoperative plasmacytoid dendritic cells secrete IFN-alpha to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence.
    Cancer Res. 2022 Sep 14. pii: 709225. doi: 10.1158/0008-5472.CAN-22-1199.
    PubMed     Abstract available
    
    
    
36. HUANG M, Long J, Yao Z, Zhao Y, et al
    METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma.
    Cancer Res. 2022 Sep 14. pii: 709196. doi: 10.1158/0008-5472.CAN-22-0963.
    PubMed     Abstract available
    
    
    
37. HU B, Zou T, Qin W, Shen X, et al
    Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma.
    Cancer Res. 2022 Sep 6. pii: 708982. doi: 10.1158/0008-5472.CAN-21-4140.
    PubMed     Abstract available
    
    
    August 2022
38. BARTON MC, Lozano G
    p53 Activation Paradoxically Causes Liver Cancer.
    Cancer Res. 2022;82:2824-2825.
    PubMed     Abstract available
    
    
    July 2022
39. PRIVES C, Suzuki S, Venkatesh D, Kanda H, et al
    GLS2 is a tumor suppressor and a regulator of ferroptosis in hepatocellular carcinoma.
    Cancer Res. 2022 Jul 27. pii: 707287. doi: 10.1158/0008-5472.CAN-21-3914.
    PubMed     Abstract available
    
    
    
40. LI Y, Li B, Xu Y, Qian L, et al
    GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
    Cancer Res. 2022 Jul 27. pii: 707288. doi: 10.1158/0008-5472.CAN-22-0042.
    PubMed     Abstract available
    
    
    
41. WANG JC, Chen DP, Lu SX, Chen JB, et al
    PIM2 expression induced by proinflammatory macrophages suppresses immunotherapy efficacy in hepatocellular carcinoma.
    Cancer Res. 2022 Jul 11. pii: 706923. doi: 10.1158/0008-5472.CAN-21-3899.
    PubMed     Abstract available
    
    
    
42. XIE C, Wang FY, Sang Y, Chen B, et al
    Mitochondrial Micropeptide STMP1 Enhances Mitochondrial Fission to Promote Tumor Metastasis.
    Cancer Res. 2022;82:2431-2443.
    PubMed     Abstract available
    
    
    June 2022
43. MOK EH, Leung CO, Zhou L, Lei MML, et al
    Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma.
    Cancer Res. 2022 Jun 29. pii: 705310. doi: 10.1158/0008-5472.CAN-21-2934.
    PubMed     Abstract available
    
    
    
44. SHAN H, Liu T, Gan H, He S, et al
    RNA helicase DDX24 stabilizes LAMB1 to promote hepatocellular carcinoma progression.
    Cancer Res. 2022 Jun 28. pii: 705275. doi: 10.1158/0008-5472.CAN-21-3748.
    PubMed     Abstract available
    
    
    
45. MAKINO Y, Hikita H, Fukumoto K, Sung JH, et al
    Constitutive activation of the tumor suppressor p53 in hepatocytes paradoxically promotes non-cell autonomous liver carcinogenesis.
    Cancer Res. 2022 Jun 13. pii: 704882. doi: 10.1158/0008-5472.CAN-21-4390.
    PubMed     Abstract available
    
    
    May 2022
46. HEINZ MC, Peters NA, Oost KC, Lindeboom RGH, et al
    Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage.
    Cancer Res. 2022;82:1953-1968.
    PubMed     Abstract available
    
    
    
47. LIU Z, Ye Y, Liu Y, Liu Y, et al
    RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1.
    Cancer Res. 2022;82:1937-1952.
    PubMed     Abstract available
    
    
    April 2022
48. CHENG Y, Bai F, Ren X, Sun R, et al
    Phosphoinositide-Binding Protein TIPE1 Promotes Alternative Activation of Macrophages and Tumor Progression via PIP3/Akt/TGFbeta Axis.
    Cancer Res. 2022;82:1603-1616.
    PubMed     Abstract available
    
    
    
49. BAYARD Q, Cordier P, Peneau C, Imbeaud S, et al
    Structure, Dynamics, and Impact of Replication Stress-Induced Structural Variants in Hepatocellular Carcinoma.
    Cancer Res. 2022 Apr 8:OF1-OF12. doi: 10.1158/0008-5472.CAN-21-3665.
    PubMed     Abstract available
    
    
    January 2022
50. LI J, Hu ZQ, Yu S, Mao L, et al
    CircRPN2 inhibits aerobic glycolysis and metastasis in hepatocellular carcinoma.
    Cancer Res. 2022 Jan 19. pii: 0008-5472.CAN-21-1259.
    PubMed     Abstract available
    
    
    
51. ADACHI Y, Kamiyama H, Ichikawa K, Fukushima S, et al
    Inhibition of FGFR Reactivates IFNgamma Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
    Cancer Res. 2022;82:292-306.
    PubMed     Abstract available
    
    
    December 2021
52. MA WK, Voss DM, Scharner J, Costa ASH, et al
    ASO-based PKM splice-switching therapy inhibits hepatocellular carcinoma growth.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-20-0948.
    PubMed     Abstract available
    
    
    
53. CHEN Y, Ling Z, Cai X, Xu Y, et al
    Activation of YAP1 by N6-methyladenosine-modified CircCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
    Cancer Res. 2021 Dec 16. pii: 0008-5472.CAN-21-1628.
    PubMed     Abstract available
    
    
    
54. XU F, Tong M, Tong CSW, Chan BKC, et al
    A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
    Cancer Res. 2021;81:6219-6232.
    PubMed     Abstract available
    
    
    
55. BELLIDO MOLIAS F, Sim A, Leong KW, An O, et al
    Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer.
    Cancer Res. 2021;81:5849-5861.
    PubMed     Abstract available
    
    
    November 2021
56. PEASE DR, Fernandez-Zapico ME
    mTOR-Dependent ARID1A Degradation: A New Twist in the Genetic-Epigenetic Interplay Driving Hepatocellular Carcinoma.
    Cancer Res. 2021;81:5608-5610.
    PubMed     Abstract available
    
    
    
57. REN X, Rong Z, Liu X, Gao J, et al
    The protein kinase activity of NME7 activates Wnt/beta-Catenin signaling to promote one-carbon metabolism in hepatocellular carcinoma.
    Cancer Res. 2021 Nov 11. pii: 0008-5472.CAN-21-1020.
    PubMed     Abstract available
    
    
    
58. SENDI H, Yazdimamaghani M, Hu M, Sultanpuram N, et al
    Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis.
    Cancer Res. 2021 Nov 9. pii: 0008-5472.CAN-21-2269.
    PubMed     Abstract available
    
    
    October 2021
59. BARCENA-VARELA M, Lujambio A
    A Novel Long Noncoding RNA Finetunes the DNA Damage Response in Hepatocellular Carcinoma.
    Cancer Res. 2021;81:4899-4900.
    PubMed     Abstract available
    
    
    September 2021
60. LOH JJ, Li TW, Zhou L, Wong TL, et al
    FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness.
    Cancer Res. 2021 Sep 22. pii: 0008-5472.CAN-20-4226.
    PubMed     Abstract available
    
    
    
61. KAN X, Zhou G, Zhang F, Ji H, et al
    Interventional Optical Imaging Permits Instant Visualization of Pathological Zones of Ablated Tumor Periphery and Residual Tumor Detection.
    Cancer Res. 2021;81:4594-4602.
    PubMed     Abstract available
    
    
    August 2021
62. ZHANG S, Zhou YF, Cao J, Burley SK, et al
    mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
    Cancer Res. 2021 Aug 24. pii: 0008-5472.CAN-21-0206.
    PubMed     Abstract available
    
    
    July 2021
63. UNFRIED JP, Marin-Baquero M, Rivera-Calzada A, Razquin N, et al
    Long noncoding RNA NIHCOLE promotes ligation efficiency of DNA double-strand breaks in hepatocellular carcinoma.
    Cancer Res. 2021 Jul 28. pii: 0008-5472.CAN-21-0463.
    PubMed     Abstract available
    
    
    
64. QIU X, Yang S, Wang S, Wu J, et al
    M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.
    Cancer Res. 2021 Jul 23. pii: 0008-5472.CAN-21-0468.
    PubMed     Abstract available
    
    
    
65. TANG M, Yang M, Wu G, Mo S, et al
    Epigenetic Induction of Mitochondrial Fission Is Required for Maintenance of Liver Cancer-Initiating Cells.
    Cancer Res. 2021;81:3835-3848.
    PubMed     Abstract available
    
    
    
66. PARK M, Kim JW, Kim KM, Kang S, et al
    Circulating Small Extracellular Vesicles Activate TYRO3 to Drive Cancer Metastasis and Chemoresistance.
    Cancer Res. 2021;81:3539-3553.
    PubMed     Abstract available
    
    
    June 2021
67. SHRIKI A, Lanton T, Sonnenblick A, Levkovitch-Siany O, et al
    Multiple Roles of IL-6 in Hepatic Injury, Steatosis, and Senescence Aggregate to Suppress Tumorigenesis.
    Cancer Res. 2021 Jun 11. pii: 0008-5472.CAN-21-0321.
    PubMed     Abstract available
    
    
    
68. GONZALEZ-ROMERO F, Mestre D, Aurrekoetxea I, O'Rourke CJ, et al
    E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
    Cancer Res. 2021;81:2874-2887.
    PubMed     Abstract available
    
    
    
69. LULLI M, Del Coco L, Mello T, Sukowati C, et al
    DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer.
    Cancer Res. 2021;81:2861-2873.
    PubMed     Abstract available
    
    
    May 2021
70. ZHAO Z, Gad H, Benitez-Buelga C, Sanjiv K, et al
    NEIL3 prevents senescence in hepatocellular carcinoma by repairing oxidative lesions at telomeres during mitosis.
    Cancer Res. 2021 May 27. pii: 0008-5472.CAN-20-1028.
    PubMed     Abstract available
    
    
    
71. MA APY, Yeung CLS, Tey SK, Mao X, et al
    Suppression of ACADM-mediated fatty acid oxidation promotes hepatocellular carcinoma via aberrant Cav1/SREBP-1 signaling.
    Cancer Res. 2021 May 11. pii: 0008-5472.CAN-20-3944.
    PubMed     Abstract available
    
    
    April 2021
72. LEUNG HW, Leung CO, Lau EY, Chung KPS, et al
    EPHB2 activates beta-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma.
    Cancer Res. 2021 Apr 26. pii: 0008-5472.CAN-21-0184.
    PubMed     Abstract available
    
    
    
73. DU L, Li Y, Kang M, Feng M, et al
    USP48 is upregulated by Mettl14 to attenuate hepatocellular carcinoma via regulating SIRT6 stabilization.
    Cancer Res. 2021 Apr 26. pii: 0008-5472.CAN-20-4163.
    PubMed     Abstract available
    
    
    
74. RICCIOTTI E, Wangensteen KJ, FitzGerald GA
    Aspirin in hepatocellular carcinoma.
    Cancer Res. 2021 Apr 23. pii: 0008-5472.CAN-21-0758.
    PubMed     Abstract available
    
    
    
75. FUHRMAN BJ, Moore SC, Byrne C, Makhoul I, et al
    Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts.
    Cancer Res. 2021;81:2246-2255.
    PubMed     Abstract available
    
    
    
76. BROADFIELD LA, Duarte JAG, Schmieder R, Broekaert D, et al
    Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis.
    Cancer Res. 2021;81:1988-2001.
    PubMed     Abstract available
    
    
    February 2021
77. ZHOU J, Li Q, Cao Y
    Spatiotemporal Heterogeneity Across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer.
    Cancer Res. 2021 Feb 15. pii: 0008-5472.CAN-20-3665.
    PubMed     Abstract available
    
    
    
78. DAVENPORT ML, Echols JB, Silva AD, Anderson JC, et al
    miR-31 displays subtype specificity in lung cancer.
    Cancer Res. 2021 Feb 8. pii: 0008-5472.CAN-20-2769.
    PubMed     Abstract available
    
    
    January 2021
79. YAMADA K, Oikawa T, Kizawa R, Motohashi S, et al
    Unconventional Secretion of PKCdelta Exerts Tumorigenic Function via Stimulation of ERK1/2 Signaling in Liver Cancer.
    Cancer Res. 2021;81:414-425.
    PubMed     Abstract available
    
    
    
80. HONG SH, Son KH, Ha SY, Wee TI, et al
    Nucleoporin 210 Serves a Key Scaffold for SMARCB1 in Liver Cancer.
    Cancer Res. 2021;81:356-370.
    PubMed     Abstract available
    
    
    
81. GENG Y, Fan J, Chen L, Zhang C, et al
    A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and Cancer Cells Regulates Pancreatic Cancer Metastasis.
    Cancer Res. 2021;81:64-76.
    PubMed     Abstract available
    
    
    
82. BATTISTELLI C, Garbo S, Riccioni V, Montaldo C, et al
    Design and Functional Validation of a Mutant Variant of the LncRNA HOTAIR to Counteract Snail Function in Epithelial-to-Mesenchymal Transition.
    Cancer Res. 2021;81:103-113.
    PubMed     Abstract available
    
    
    October 2020
83. WILLS CA, Liu X, Chen L, Zhao Y, et al
    Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1976.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.